Here, we compile the Biopharmaceutics Drug Disposition Classification System (BDDCS) classification for 927 drugs, which include 30 active metabolites. Of the 897 parent drugs, 78.8% (707) are administered orally. Where the lowest measured solubility is found, this value is reported for 72.7% (513) of these orally administered drugs and a dose number is recorded. The measured values are reported for percent excreted unchanged in urine, LogP, and LogD 7.4 when available. For all 927 compounds, the in silico parameters for predicted Log solubility in water, calculated LogP, polar surface area, and the number of hydrogen bond acceptors and hydrogen bond donors for the active moiety are also provided, thereby allowing comparison analyses for both in silico and experimentally measured values. We discuss the potential use of BDDCS to estimate the disposition characteristics of novel chemicals (new molecular entities) in the early stages of drug discovery and development. Transporter effects in the intestine and the liver are not clinically relevant for BDDCS class 1 drugs, but potentially can have a high impact for class 2 (efflux in the gut, and efflux and uptake in the liver) and class 3 (uptake and efflux in both gut and liver) drugs. A combination of high dose and low solubility is likely to cause BDDCS class 4 to be underpopulated in terms of approved drugs (N = 53 compared with over 200 each in classes 1–3). The influence of several measured and in silico parameters in the process of BDDCS category assignment is discussed in detail.
Key wordsBDDCS biowaiver dose number extent of metabolism permeability rate
The authors were supported in part in preparation of the five tables and this manuscript by NIH grants GM-61390, GM-75900 and GM-90457 (LZB), and by GM-095952, MH-084690, and CA-118100 (TIO). We thank Molecular Discovery Ltd. and Professor Cruciani for the VolSurf+ suite license.
Supporting Info Available
An excel file is available as supporting info containing the following data for the 927 drugs dataset: name, BDDCS class, max dose strength value, max dose strength unit, formulation, route, measured solubility, dose number, % excreted unchanged in urine, MW drug, MW solution, pDose, measured LogS molar, measured LogP, measured LogD 7.4, ALOGPS 2.1 solubility, cDose Number (ALOGPS based), minVSLgS, cDose Number (minVSLgS based), cLogP, HBA,HBD, PSA, and violations to Rules of Five. Definitions for the terms used only in the supporting info file may be found at the end of that data set. In addition, box plots of minVSLgS, ALOGPS 2.1 solubility, MLogP, cLogP, MW, PSA parameters against BDDCS are provided.
- 4.Food and Drug Administration. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Food and Drug Administration, Rockville, MD. 2000. www.fda.gov/cder/guidance/index.htm.
- 9.European Medicines Agency. Guideline on the investigation of bioequivalence. Doc. Ref.:CPMP/EWP/QWP/1401/98 Rev.1/Corr. http://www.ema.europa.eu/pdfs/human/qwp/140198enrev1fin.pdf. Accessed 28 March 2010.
- 12.Lyrica™ package insert. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=42134#nlm34090-1.
- 14.Matthews EJ, Krulak NL, Benz RD, Contrera JF. Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data. Curr Drug Discov Technol. 2004;1:61–76.PubMedCrossRefGoogle Scholar
- 22.Zheng HX, Huang Y, Frassetto Y, Benet LZ. Elucidating rifampin’s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009;85:78–85.PubMedCrossRefGoogle Scholar
- 24.Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos. 2006;34:1175–81.PubMedCrossRefGoogle Scholar
- 26.Sussman NL, Waltershied M, Butler T, Cali JJ, Riss T, Kelly JH. The predictive nature of high throughput toxicity screening using a human hepatocyte cell line. Cell Notes. 2002;3:7–10.Google Scholar
- 43.The VolSurf + program, version 1.0.4 is distributed by Molecular Discovery Ltd. http://www.moldiscovery.com.
- 47.Thummel KE, Shen DD, Isoherranen N. Design and optimization of dosage regimens: pharmacokinetic data. In: Brunton L, Chabner B, Knollman B, editors. Goodman and Gilman’s the pharmacological basis of therapeutics, vol. 12th. New York: McGraw-Hill; 2011. p. 1891–990 (Appendix II).Google Scholar
- 48.Olah M, Rad R, Ostopovici L, Bora A, Hadaruga N, Hadaruga D, et al. WOMBAT and WOMBAT-PK: bioactivity databases for lead and drug discovery. In: Schreiber SL, Kapoor TM, Wess G, editors. Chemical biology: from small molecules to systems biology and drug design. Weinheim: Wiley-VCH; 2007. p. 760–86.Google Scholar